Seattle, WA, Aug-10, 2018 — / Industry Chronicle News / —
In October 2017, Government of the U.S. declared the opioid crisis, as a public health emergency. This declaration is expected to increase the awareness about the drug overuse or abuse and it led the doctors to reduce from over-prescribing the opioids drug. Moreover, Attorney General of more than 35 states sent a letter to the America’s Health Insurance Plans, national association whose members provide coverage for health care and related services, urging its members to reconsider coverage policies that may be fueling the growth of opioid crisis.
Due to low cost of opioids compared with other painkillers such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, the insurance company has covered the opioid but not costly one which resulted in limited access to costly painkillers. This is the major concern for all states and letter from Attorney general of the states have been sent to modify this coverage policy so that every painkiller have equal access.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1048
U.S. Opioids Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The U.S. Opioids market research report is a professional and in-depth study on the current state of U.S. Opioids Industry.
According to the National Center for Health Statistics (NCHS), a division of the Centers for Disease Control and Prevention, (CDC) in 2017, drug overdose killed around 64,070 people in the U.S. in 2016, a rise of 21% over the 52,898 drug overdose deaths was recorded in 2015 and death due to synthetic-opioid fatalities more than doubling in number during the same time increasing from 9,945 in 2015 -2016 to 20,145 in 2016 – 2017.
Key Vendors of U.S. Opioids Market: Some major players operating in the U.S. opioids market include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals plc, Allergan, plc, and Pfizer Inc.
U.S. Opioids market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1048
Regions of U.S. Opioids market:
In the end, the report makes some important proposals for a new project of U.S. Opioids Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2016-2020 global U.S. Opioids industry covering all important parameters.
U.S. Opioids driver
U.S. Opioids challenge
U.S. Opioids trend
The U.S. Opioids market is expected to exhibit a CAGR of 5.2% over the forecast period (2017 – 2025), owing to the increasing incidences of chronic pain, especially in emerging economies.
Opioids overuse or abuse, which is contributing significantly to this market expansion has become the major concern in the economy.
Alternative drugs like cannabis has gained attraction in recent times for pain management. If proven effective and safe, cannabis has potential to replace the opioids.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1048